Osteonecrosis of the jaw induced by administration of bisphosphonates (BPs), BP-related osteonecrosis (BRONJ), typically develops after tooth extraction and is medically challenging. As BPs inhibit oral mucosal cell growth, we hypothesized that suppression of the wound healing-inhibiting effects could prevent BRONJ onset after tooth extraction. Since basic fibroblast growth factor (bFGF) promotes wound healing, but has a short half-life, we examined whether the initiation of BRONJ could be prevented by applying a bFGF-containing gelatin hydrogel over the extraction sockets of BRONJ model rats. Forty-three rats, received two intravenous injections of zoledronic acid 60 μg/kg, once per week for a period of 2 weeks, underwent extraction of a u...
Bisphosphonates (BPs) have been used clinically for over 30 years to treat postmenopausal osteoporos...
Aim: The aim of this study is to replicate both clinical and histological presentation of bisphospho...
Objective: Bisphosphonates, the most common anti-resorptive medications, are internalized by osteocl...
Osteonecrosis of the jaw induced by administration of bisphosphonates (BPs), BP-related osteonecrosi...
Osteonecrosis of the jaw induced by administration of bisphosphonates (BPs), BP-related osteonecrosi...
Abstract Antiresorptive or antiangiogenic drugs can cause medication-related osteonecrosis of the ja...
Medication-related osteonecrosis of the jaw (MRONJ) still poses an enigma for clinicians and researc...
BACKGROUND: This work aimed at determining whether bisphosphonate therapy produces a sufficient cond...
Bisphosphonate (BP)-related osteonecrosis of the jaw, previously known as BRONJ, now referred to mor...
We evaluated the side effects of bisphosphonate (BP) on tooth extraction socket healing in spontaneo...
Despite the acknowledged benefit of bisphosphonates (BPs) in controlling bone disorders characterize...
Bisphosphonates cause osteoclast apoptosis, thus inhibiting bone resorption and reducing bone loss. ...
Background: Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) disease is rare, but there ...
Medication‐related osteonecrosis of the jaw (MRONJ) poses an ongoing challenge for clinicians and re...
Bisphosphonates (BP) like Zometa (ZA) are widely used to treat complications of bony metastases in c...
Bisphosphonates (BPs) have been used clinically for over 30 years to treat postmenopausal osteoporos...
Aim: The aim of this study is to replicate both clinical and histological presentation of bisphospho...
Objective: Bisphosphonates, the most common anti-resorptive medications, are internalized by osteocl...
Osteonecrosis of the jaw induced by administration of bisphosphonates (BPs), BP-related osteonecrosi...
Osteonecrosis of the jaw induced by administration of bisphosphonates (BPs), BP-related osteonecrosi...
Abstract Antiresorptive or antiangiogenic drugs can cause medication-related osteonecrosis of the ja...
Medication-related osteonecrosis of the jaw (MRONJ) still poses an enigma for clinicians and researc...
BACKGROUND: This work aimed at determining whether bisphosphonate therapy produces a sufficient cond...
Bisphosphonate (BP)-related osteonecrosis of the jaw, previously known as BRONJ, now referred to mor...
We evaluated the side effects of bisphosphonate (BP) on tooth extraction socket healing in spontaneo...
Despite the acknowledged benefit of bisphosphonates (BPs) in controlling bone disorders characterize...
Bisphosphonates cause osteoclast apoptosis, thus inhibiting bone resorption and reducing bone loss. ...
Background: Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) disease is rare, but there ...
Medication‐related osteonecrosis of the jaw (MRONJ) poses an ongoing challenge for clinicians and re...
Bisphosphonates (BP) like Zometa (ZA) are widely used to treat complications of bony metastases in c...
Bisphosphonates (BPs) have been used clinically for over 30 years to treat postmenopausal osteoporos...
Aim: The aim of this study is to replicate both clinical and histological presentation of bisphospho...
Objective: Bisphosphonates, the most common anti-resorptive medications, are internalized by osteocl...